Comerica Bank Has $1.24 Million Stake in Charles River Laboratories International, Inc. $CRL

Key Points

• Comerica Bank cut its stake in Charles River Laboratories by 55.8% in the fourth quarter, leaving it with 6,197 shares worth about $1.24 million.
• Charles River reported better-than-expected Q1 results, with EPS of $2.06 versus $1.96 expected and revenue of $995.8 million versus $977.5 million expected.
• Despite the earnings beat, the stock faces mixed sentiment: analysts maintain a Moderate Buy consensus with an average price target of $205.86, but concerns remain about margin pressure and muted growth.

Comerica Bank trimmed its position in shares of Charles River Laboratories International, Inc. (NYSE:CRL - Free Report) by 55.8% in the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 6,197 shares of the medical research company's stock after selling 7,829 shares during the period. Comerica Bank's holdings in Charles River Laboratories International were worth $1,236,000 as of its most recent SEC filing.

A number of other institutional investors have also made changes to their positions in CRL. Tema Etfs LLC bought a new stake in Charles River Laboratories International during the 4th quarter valued at approximately $26,000. Rothschild Investment LLC increased its position in Charles River Laboratories International by 82.4% in the 3rd quarter. Rothschild Investment LLC now owns 186 shares of the medical research company's stock worth $29,000 after buying an additional 84 shares during the period. Atlantic Union Bankshares Corp acquired a new position in shares of Charles River Laboratories International during the third quarter worth approximately $31,000. Geneos Wealth Management Inc. lifted its holdings in shares of Charles River Laboratories International by 98.0% during the second quarter. Geneos Wealth Management Inc. now owns 293 shares of the medical research company's stock worth $44,000 after buying an additional 145 shares during the last quarter. Finally, EverSource Wealth Advisors LLC boosted its position in shares of Charles River Laboratories International by 51.0% in the third quarter. EverSource Wealth Advisors LLC now owns 308 shares of the medical research company's stock valued at $48,000 after acquiring an additional 104 shares during the period. 98.91% of the stock is currently owned by institutional investors.

Charles River Laboratories International Stock Performance

Shares of NYSE CRL opened at $177.96 on Friday. The business has a fifty day simple moving average of $170.79 and a 200 day simple moving average of $183.34. The company has a current ratio of 1.36, a quick ratio of 1.02 and a debt-to-equity ratio of 0.90. The firm has a market capitalization of $8.78 billion, a price-to-earnings ratio of -47.33, a PEG ratio of 2.20 and a beta of 1.44. Charles River Laboratories International, Inc. has a one year low of $132.58 and a one year high of $228.88.

Charles River Laboratories International (NYSE:CRL - Get Free Report) last posted its quarterly earnings results on Thursday, May 7th. The medical research company reported $2.06 earnings per share for the quarter, topping analysts' consensus estimates of $1.96 by $0.10. The firm had revenue of $995.83 million for the quarter, compared to the consensus estimate of $977.46 million. Charles River Laboratories International had a negative net margin of 4.59% and a positive return on equity of 15.36%. The business's revenue was up 1.2% compared to the same quarter last year. During the same quarter in the previous year, the company earned $2.34 earnings per share. Charles River Laboratories International has set its FY 2026 guidance at 10.800-11.300 EPS. Sell-side analysts expect that Charles River Laboratories International, Inc. will post 10.97 EPS for the current year.

Key Charles River Laboratories International News

Here are the key news stories impacting Charles River Laboratories International this week:

• Positive Sentiment: Charles River reported Q1 EPS of $2.06, ahead of the $1.96 consensus, and revenue of $995.8 million, also above estimates. Reuters article
• Positive Sentiment: Reuters noted steady demand for drug discovery and development services, suggesting the core business is stabilizing. Reuters article
• Neutral Sentiment: Management reaffirmed full-year 2026 EPS guidance of $10.80 to $11.30, which is in line with expectations but not a major upside surprise. Earnings release and transcript
• Negative Sentiment: Investors appear concerned that margin compression and weak organic growth may offset the earnings beat, which helps explain the stock’s weakness. Zacks article
• Negative Sentiment: One recent analyst note downgraded CRL to Sell, citing a strong share rally, muted near-term growth, and longer-term risks. Seeking Alpha article

Analysts Set New Price Targets

CRL has been the topic of several research analyst reports. TD Cowen lowered their price objective on shares of Charles River Laboratories International from $251.00 to $235.00 and set a "buy" rating on the stock in a research note on Friday, February 20th. Weiss Ratings reiterated a "sell (d)" rating on shares of Charles River Laboratories International in a research note on Monday, April 20th. JPMorgan Chase & Co. decreased their price target on shares of Charles River Laboratories International from $165.00 to $160.00 and set a "neutral" rating on the stock in a research report on Monday, April 13th. UBS Group boosted their price objective on shares of Charles River Laboratories International from $170.00 to $175.00 and gave the stock a "neutral" rating in a report on Wednesday, February 25th. Finally, Citigroup increased their target price on shares of Charles River Laboratories International from $200.00 to $265.00 and gave the company a "buy" rating in a research note on Friday, January 16th. Eleven analysts have rated the stock with a Buy rating, four have issued a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat, the stock has a consensus rating of "Moderate Buy" and an average target price of $205.86.

Charles River Laboratories International Company Profile

Charles River Laboratories International, Inc is a leading provider of research models and preclinical and clinical support services for the pharmaceutical, biotechnology and medical device industries. The company's core offerings include discovery, safety assessment, toxicology, and pathology services, as well as supply of laboratory animals and related diagnostics. Services extend across in vivo and in vitro testing, biologics testing, and support for advanced therapies, helping clients accelerate drug development from early discovery through regulatory submission.

Founded in 1947 in Wilmington, Massachusetts, Charles River has grown through strategic investments and acquisitions to establish a broad portfolio of capabilities.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.